title: Vitiligo after combination therapy of pegylated interferon-α-2a, ribavirin and vitamin D in a patient with chronic hepatitis C.
authors.affiliation: Department of Dermatology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan.
authors.forename: Naoki
authors.initials: N
authors.lastname: Oiso
authors.forename: Masako
authors.initials: M
authors.lastname: Sato
authors.forename: Akira
authors.initials: A
authors.lastname: Kawada
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects*; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects*; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins / Q000009:adverse effects; D012254:Ribavirin / Q000009:adverse effects; D014807:Vitamin D / Q000008:administration & dosage; D014808:Vitamin D Deficiency / Q000150:complications*; D014820:Vitiligo / Q000209:etiology*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D014807:Vitamin D; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a